A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

The duration of treatment is 6 weeks.

Inclusion Criteria:

• Healthy children 12 to 18 months of age.

Exclusion Criteria:

• Previous receipt of measles, mumps, rubella and/or varicella vaccine.
• Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster.
• Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy.
• History of seizures (convulsions)
• Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin.
• A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F [37.5° C]).